文献速递母胎医学产科

产前染色体微阵列分析检出的低外显率神经易感性基因座的遗传咨询困境

Dilemmas in genetic counseling for low-penetrance neuro-susceptibility loci detected on prenatal chromosomal microarray analysis.
PubMed 文献 · Am J Obstet Gynecol · 2017-11-14

该研究在2014年1月至2015年12月期间进行了700例产前染色体微阵列分析,分为有指征组(n=375)和患者选择组(n=325)。有指征组临床显著拷贝数变异检出率为3.7%(14/375),患者选择组为0.6%(2/325)(P=.009);低外显率神经易感性基因座在两组检出率相似(3.7% vs 3.4%;P=.85)。作者认为产前染色体微阵列分析在两组中均提供了临床显著信息,但也在约3.5%的病例中检出低外显率神经易感性基因座,应在检测前咨询中告知患者。

要点

  • 有指征组临床显著拷贝数变异检出率3.7%(14/375),患者选择组0.6%(2/325),差异有统计学意义(P=.009)。
  • 低外显率神经易感性基因座在两组检出率相似:有指征组3.7% vs 患者选择组3.4%(P=.85)。
  • 作者认为检测前咨询应告知患者可能检出低外显率神经易感性基因座,尤其在患者选择进行染色体微阵列分析时。

核心结论

  • 产前染色体微阵列分析在有指征组和患者选择组中均提供了临床显著信息,但也在约3.5%的病例中检出低外显率神经易感性基因座。
  • 作者认为这一事实应在检测前咨询中告知患者,以便患者做出知情选择,尤其在患者选择进行染色体微阵列分析时。

研究设计与样本

  • 研究期间(2014年1月至2015年12月)共进行700例产前染色体微阵列分析。
  • 病例分为有指征组(n=375,超声异常或提示性病史)和患者选择组(n=325,胎儿结构正常且无其他特殊指征)。
  • 实验室报告与遗传综合征相关基因座中≥400 Kb的拷贝数变异,以及其他基因组区域≥1 Mb的拷贝数变异。
  • 结果分类为大体非整倍体、拷贝数变异和正常;拷贝数变异按美国医学遗传学与基因组学学会标准与指南分为致病性、意义未明变异和良性。
  • 意义未明变异进一步分为可能致病性、未细分意义未明变异和可能良性。

主要发现

  • 患者选择组病例随时间推移变得更普遍(研究开始时35.5%,研究期末48.4%)。
  • 有指征组临床显著拷贝数变异检出率为3.7%(14/375),患者选择组为0.6%(2/325)(P=.009)。
  • 所有「可能良性」变异均由低外显率神经易感性基因座组成,其发生率在有指征组与患者选择组之间相似(3.7% vs 3.4%;P=.85)。
  • 在有指征组中,一些意义未明变异可能对异常解剖发现有所贡献。
  • 在患者选择组中,低外显率神经易感性基因座的发现常常是意外的,并对准父母造成困惑。

临床怎么用

  • 作者认为产前染色体微阵列分析在有指征组和患者选择组中均提供了临床显著信息。
  • 作者认为检测前咨询应告知患者可能检出低外显率神经易感性基因座,以便患者做出知情选择,尤其在患者选择进行染色体微阵列分析时。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chromosomal microarray analysis is standard of care in fetuses with malformations, detecting clinically significant copy number variants in 5-7% of cases over conventional karyotyping. However, it also detects variants of uncertain significance in 1.6-4.2% of the cases, some of which are low-penetrance neuro-susceptibility loci. The interpretation of these variants in pregnancy is particularly challenging because the significance is often unclear and the clinical implications may be difficult to predict. OBJECTIVE: The purpose of this study was to describe counseling dilemmas regarding low-penetrance neuro-susceptibility loci that are detected by prenatal chromosomal microarray analysis. STUDY DESIGN: During the study period (January 2014 to December 2015), 700 prenatal chromosomal microarray analyses were performed. Cases were categorized as "indicated" (n=375) if there were abnormal sonographic findings or suggestive medical history and "patient choice" (n=325) in the presence of a structurally normal fetus with no other particular indication. The laboratory reported on copy number variants ≥400 Kb in size in loci known to be associated with genetic syndromes and ≥1 Mb in other areas of genome. Results were classified as gross aneuploidy, copy number variants, and normal. Copy number variants were categorized according to the American College of Medical Genetics standards and guidelines: pathogenic, variants of uncertain significance, or benign. Variants of uncertain significance were further subdivided into categories of likely pathogenic, variants of uncertain significance with no subclassification, and likely benign. Statistical analysis was performed with the use of Chi square test and Fisher's exact test to compare intergroup differences in incidence of the different result categories and demographic data. RESULTS: Patient choice cases became more prevalent with time (35.5% in the beginning of the study, compared with 48.4% at the end of the study period). Clinically significant copy number variants were found in 14 of 375 (3.7%) of indicated cases vs only 2 of 325 (0.6%) of patient choice cases (P=.009). All "likely benign" variants consisted of low-penetrance neuro-susceptibility loci. The incidence thereof was similar between the indicated and patient choice groups (3.7% vs 3.4%; P=.85). In the indicated group, some variants of uncertain significance may have contributed to the abnormal anatomic findings. Conversely, in the patient choice group, the finding of low-penetrance neuro-susceptibility loci was often unexpected and confounding for prospective parents. CONCLUSION: Prenatal chromosomal microarray analysis added clinically significant information in both groups. However, it also detected low-penetrance neuro-susceptibility loci in approximately 3.5% of the cases. This fact should be conveyed during pretest counseling to allow patients to make informed choices, particularly when chromosomal microarray is to be performed for patient choice.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Brabbing-Goldstein D, Reches A, Svirsky R, et al. Dilemmas in genetic counseling for low-penetrance neuro-susceptibility loci detected on prenatal chromosomal microarray analysis. Am J Obstet Gynecol. 2017. PMID: 29146387. doi:10.1016/j.ajog.2017.11.559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。